CIBC Asset Management
KROS icon

CIBC Asset Management’s Keros Therapeutics KROS Stock Holding History

CIBC Asset Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-47,304
Closed -$2.02M – 1110
2023
Q1 		$2.02M Sell
47,304
-42,842
-48% -$2.16M 0.01% 551
2022
Q4 		$4.33M Sell
90,146
-56,222
-38% -$2.63M 0.02% 388
2022
Q3 		$5.51M Buy
+146,368
New +$5.07M 0.02% 317

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

CIBC Asset Management's KROS Position: Q2 2023 in Review

CIBC Asset Management sold out of Keros Therapeutics (KROS) in Q2 2023, closing a stake of 47,304 shares — an estimated $2.02M sold.

CIBC Asset Management first reported a position in KROS in Q3 2022 and held it in 3 quarters. The position peaked at $5.51M in Q3 2022. 123 funds tracked by Wall St. Rank hold KROS as of Q2 2023.

  • CIBC Asset Management reported no remaining Keros Therapeutics position as of Q2 2023 after selling out during the quarter.
  • CIBC Asset Management sold 47,304 Keros Therapeutics shares in Q2 2023, an estimated $2.02M.
  • CIBC Asset Management first reported a position in Keros Therapeutics in Q3 2022 and held it in 3 quarters.
  • CIBC Asset Management's Keros Therapeutics position peaked at $5.51M in Q3 2022.
  • 123 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2023.

Based on CIBC Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.